CPT-Pharmacometrics & Systems Pharmacology

Article	Citations
Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery	85
Evaluation of covariate effects in item response theory models	50
Issue Information	44
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients	40
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models	39
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children	37
Issue Information	37
Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval	36
Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population	32
Issue Information	29
Correction to Network module‐based drug repositioning for pulmonary arterial hypertension	27
End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor	26
A quantitative systems pharmacology approach to support mRNA vaccine development and optimization	25
Pharmacometric and statistical considerations for dose optimization	25
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies	25
Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models	25
Issue Information	24
Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP‐1	23
Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report	23
Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential	23
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist	22
Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story	22
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II	22
A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach	21
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach	21

Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates	21
Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr	21
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy	21
Response to ‘Modeling is data driven: Use it for successful virtual patient generation’	20
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations	20
Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin	19
Update to improve reproducibility and interpretability: A response to “Machine Learning for Tumor Growth Inhibition”	19
A population pharmacokinetic‐pharmacodynamic model of YH12852, a highly selective 5‐hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation	18
Quantitative systems toxicology modeling in pharmaceutical research and development: An industry‐wide survey and selected case study examples	18
Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients	18
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration	18
Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors	18
Application of a dual mechanistic approach to support bilastine dose selection for older adults	18
Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine	17
The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens	17
Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women	17
Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution	16
Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham	16
Issue Information	16
Regulatory utility of physiologically‐based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report	16
Issue Information	16
Tutorial on model selection and validation of model input into precision dosing software for model‐informed precision dosing	16
Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel	15
Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response	15
Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia	15
Physiologically based pharmacokinetic modeling of drug–drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy	15
A physiologically‐based pharmacokinetic modeling approach for dosing amiodarone in children on ECMO	15
Metaheuristics for pharmacometrics	14
Activity and perspective on quantitative modeling and simulation in Japan: Update from the Pharmaceuticals and Medical Devices Agency	14
Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia	14
Population Pharmacokinetics and Transfer of Gabapentin When Used as a Pain Adjunct for Cesarean Deliveries	14
Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles	14
Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact	14
	14
Modeling of Disease Progression of Type 2 Diabetes Using Real‐World Data: Quantifying Competing Risks of Morbidity and Mortality	14
Pharm‐AutoML: An open‐source, end‐to‐end automated machine learning package for clinical outcome prediction	14
Variable or variate? A conundrum in pharmacometrics exposure–response models	14
	13
CYTOCON: The manually curated database of human in vivo cell and molecule concentrations	13
Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials	13
The interaction of core modules as a basis for elucidating network behavior determining Parkinson's disease pathogenesis	13
Model‐based evaluation of image‐guided fractionated whole‐brain radiation therapy in pediatric diffuse intrinsic pontine glioma xenografts	13
Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin	13
Flexible and efficient Bayesian pharmacometrics modeling using Stan and Torsten, Part I	13
Longitudinal and time‐to‐event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma	13
Mechanistic pharmacokinetic–pharmacodynamic modeling and simulations of naloxone auto‐injector 10 mg reversal of opioid‐induced respiratory depression	13
A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection	13
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases	12
Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases	12
Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus	12

Development of and insights from systems pharmacology models of antibody‐drug conjugates	12
Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non‐small cell lung cancer based on bintrafusp alfa trials	12
Issue Information	12
Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study	12
Mid‐dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients	12
Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials	12
	12
Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps	12
A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling	12
Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma	11
The influence of flip‐flop in population pharmacokinetic analyses	11
Low‐dimensional neural ordinary differential equations accounting for inter‐individual variability implemented in Monolix and NONMEM	11
Quantitative system pharmacology as a legitimate approach to examine extrapolation strategies used to support pediatric drug development	11
Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss–Newton Method	11
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates	11
	11
	11
Type 1 diabetes prevention clinical trial simulator: Case reports of model‐informed drug development tool	11
Cytochrome P450 2D6 genotype–phenotype characterization through population pharmacokinetic modeling of tedatioxetine	11
A Model‐Based Approach to Evaluate Anti‐Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T‐Cell Bispecific Cibisatamab	11
Population pharmacokinetic modeling of zavegepant, a calcitonin gene‐related peptide receptor antagonist, in healthy adults and patients with migraine	11
Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview	11
Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B	11
Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer	10
Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model	10
Population pharmacokinetic modeling of oral brepocitinib in healthy volunteers and patients with immuno‐inflammatory diseases	10
Semimechanistic modeling of copeptin and aldosterone kinetics and dynamics in response to rehydration treatment for diabetic ketoacidosis in children	10
Issue Information	10
Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling	10
Item performance of the scale for the assessment and rating of ataxia in rare and ultra‐rare genetic ataxias	10
Nivolumab exposure–response analysis for adjuvant treatment of melanoma supporting a change in posology	10
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager g	10
Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach	10
Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin	10
PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?	10
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it?	9
Predicting the longitudinal changes of levodopa dose requirements in Parkinson’s disease using item response theory assessment of real‐world Unified Parkinson's Disease Rating Scale	9
Quantitative systems pharmacology in the age of artificial intelligence	9
Quantitative approaches to drug safety: The 2022 PSP special issue	9
Issue Information	9
Within‐chain parallelization—Giving Stan Jet Fuel for population modeling in pharmacometrics	9
Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections	9
Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target‐mediated drug disposition and OATP1B3‐mediated hepatic uptake in a physiologically based model	9
	9
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans	9
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework	9
A literature review of drug transport mechanisms during lactation	9
Issue Information	9
Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors	9
	9
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling	8
Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application	8
Development and comparison of model‐integrated evidence approaches for bioequivalence studies with pharmacokinetic end points	8
Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor	8
Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?	8
Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data	8
The area under the effect curve as an efficacy determinant for anti‐infectives	8
Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non‐small cell lung cancer	8
Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective	8
Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19	8
Predicting the correct dose in children: Role of computational Pediatric Physiological‐based pharmacokinetics modeling tools	8
Translating in vitro CFTR rescue into small molecule correctors for cystic fibrosis using the Library of Integrated Network‐based Cellular Signatures drug discovery platform	8
Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers	8
Issue Information	8
Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach	8
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer	8
Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example	8
Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients	8
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions	8
Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study	8
Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis	8
Issue Information	8
Population model‐based analysis of the memory B‐cell response following belimumab therapy in the treatment of systemic lupus erythematosus	8
Issue Information	7
	7
Predicting disease activity in patients with multiple sclerosis: An explainable machine‐learning approach in the Mavenclad trials	7
Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study	7
Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma	7
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility	7
Exposure‐response modeling for extrapolation from adult to pediatric patients who differ with respect to prognostic factors: Application to everolimus	7

Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm	7
Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision‐Making	7
Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate	7
A multi‐model approach to predict efficacious clinical dose for an anti‐TGF‐β antibody (GC2008) in the treatment of osteogenesis imperfecta	7
Deep compartment models: A deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling	7
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug	7
Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer	7
Mechanistic modeling of drug products applied to the skin: A workshop summary report	7
Quantitative systems pharmacology model of α‐synuclein pathology in Parkinson's disease‐like mouse for investigation of passive immunotherapy mechanisms	7
Abstracts	7
A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug‐induced toxicity	7
Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201	7
	7
Applying interpretable machine learning workflow to evaluate exposure–response relationships for large‐molecule oncology drugs	7
Synthetic Model Combination: A new machine‐learning method for pharmacometric model ensembling	7
Network module‐based drug repositioning for pulmonary arterial hypertension	7
Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit	7
Delineating gene–environment effects using virtual twins of patients treated with clozapine	7
A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population	7
A fully automatic tool for development of population pharmacokinetic models	7
Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis	7
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development	6
Developmental pharmacokinetics of indomethacin in preterm neonates: Severely decreased drug clearance in the first week of life	6
A framework to guide dose & regimen strategy for clinical drug development	6
Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody	6
Model‐based prediction of progression‐free survival for combination therapies in oncology	6
Corrigendum to: 2022 WCoP Abstracts	6
Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV	6
Physiologically‐based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency	6
Multistate modeling for survival analysis in critically ill patients treated with meropenem	6
Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis	6
Minimal physiologically‐based hybrid model of pharmacokinetics in pregnant women: Application to antenatal corticosteroids	6
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis	6
A quantitative systems pharmacology approach to predict the safe‐equivalent dose of doxorubicin in patients with cardiovascular comorbidity	6
Growth‐rate model predicts in vivo tumor response from in vitro data	6
Issue Information	6
	6
Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy	6
A continued learning approach for model‐informed precision dosing: Updating models in clinical practice	6
Mixed‐effects models and the drug titration paradox	6
Skipping a pillar does not make for strong foundations: Pharmacokinetic‐pharmacodynamic reasoning behind the shape of dose–response relationships in oncology	6
Issue Information	6
A best practice framework for applying physiologically‐based pharmacokinetic modeling to pediatric drug development	6
Quantitative methods and modeling to assess COVID‐19‐interrupted in vivo pharmacokinetic bioequivalence studies with two reference batches	6
Population pharmacokinetics of favipiravir in patients with COVID‐19	6
Mechanistic modeling of ophthalmic, nasal, injectable, and implant generic drug products: A workshop summary report	6
PBPK perspective on alternative CYP3A4 inducers for rifampin	5
Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine	5
	5
Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic	5
Consistent methods for fat‐free mass, creatinine clearance, and glomerular filtration rate to describe renal function from neonates to adults	5
Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach	5
Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV‐2 patients	5
Machine learning for tumor growth inhibition: Interpretable predictive models for transparency and reproducibility	5
To be or not to be, when synthetic data meet clinical pharmacology: A focused study on pharmacogenetics	5
In memoriam Lambertus (“Bert”) A. Peletier 29 March 1937–16 December 2023: Furthering quantitative pharmacology through applied mathematics	5
A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC	5
Preclinical side effect prediction through pathway engineering of protein interaction network models	5
Computational design of clinical trials using a combination of simulation and the genetic algorithm	5
An artificial neural network−pharmacokinetic model and its interpretation using Shapley additive explanations	5
Introduction of an artificial neural network–based method for concentration‐time predictions	5
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma	5
Pediatric model‐based dose optimization using a pooled exposure–response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma	5
Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat	5
Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB‐02) in Patients With Advanced Solid Tumors	5
	5
Biased computation of probability of target attainment for antimicrobial drugs	5
Issue Information	5
Development and application of a PBPK modeling strategy to support antimalarial drug development	5
CKD subpopulations defined by risk‐factors: A longitudinal analysis of electronic health records	5
Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups	5
Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data	5
Model enhanced reinforcement learning to enable precision dosing: A theoretical case study with dosing of propofol	5
Evaluation of machine learning methods for covariate data imputation in pharmacometrics	5
Quantitative systems pharmacology model of thrombopoiesis and platelet life‐cycle, and its application to thrombocytopenia based on chronic liver disease	5
	5
Integrative chemogenomic analysis identifies small molecules that partially rescue ΔF508‐CFTR for cystic fibrosis	5
Population pharmacokinetic analysis of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in patients and healthy volunteers	5
Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical‐driven balance of population average and variability	5
Hepatic OATP1B zonal distribution: Implications for rifampicin‐mediated drug–drug interactions explored within a PBPK framework	5
Application of longitudinal item response theory models to modeling Parkinson’s disease progression	5
Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action	4
Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of theDNAdamage response pathway	4
Semimechanistic models to relate noxious stimulation, movement, and pupillary dilation responses in the presence of opioids	4
A tutorial on pharmacometric Markov models	4
Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women	4
Tumor growth inhibition modeling to support the starting dose for dacomitinib	4
Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs	4
Learn–confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform	4
Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib	4
PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria	4
Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug–drug interaction predictions	4
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy	4
Construction of a prognostic model based on memory CD4+ T cell–associated genes for lung adenocarcinoma and its applications in immunotherapy	4
Berkeley Madonna Version 10–A simulation package for solving mathematical models	4